



- (51) **International Patent Classification:**  
*C12Q 1/68* (2006.01)      *C12P 19/34* (2006.01)  
*C07H 21/04* (2006.01)
- (21) **International Application Number:** PCT/US2013/039298
- (22) **International Filing Date:** 2 May 2013 (02.05.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
61/641,720      2 May 2012 (02.05.2012)      US
- (71) **Applicant: IBIS BIOSCIENCES, INC.** [US/US]; 2251 Faraday Ave.; Suite 150, Carlsbad, California 92008 (US).
- (72) **Inventor; and**
- (71) **Applicant : ESHOO, Mark W.** [US/US]; 13615 Kibbings Rd, San Diego, California 92130 (US).
- (74) **Agent: CASIMIR, David A.**; Casimir Jones S.C., 2275 Deming Way, Suite 310, Middleton, Wisconsin 53562 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*



WO 2013/166305 A1

(54) **Title:** DNA SEQUENCING

(57) **Abstract:** Provided herein is technology relating to sequencing nucleic acids and particularly, but not exclusively, to methods, compositions, and systems for sequencing a nucleic acid using two or more labels and signal ratios to distinguish bases.

## DNA SEQUENCING

### CROSS-REFERENCE TO RELATED APPLICATIONS

The present Application claims priority to U.S. Provisional Application  
5 Serial Number 61/641,720 filed 2 May 2012, the entirety of which is incorporated  
by reference herein.

### FIELD OF INVENTION

10 Provided herein is technology relating to sequencing nucleic acids and  
particularly, but not exclusively, to methods, compositions, and systems for  
sequencing a nucleic acid using at least two labels wherein the ratio of the labels  
identifies and differentiates bases.

### BACKGROUND

15 DNA sequencing is driving genomics research and discovery. The  
completion of the Human Genome Project was a monumental achievement  
involving an incredible amount of combined efforts among genome centers and  
scientists worldwide. This decade-long project was completed using the Sanger  
sequencing method, which remains the staple genome sequencing methodology  
20 in high-throughput genome sequencing centers. The main reason behind the  
prolonged success of this method was its basic and efficient, yet elegant, method  
of dideoxy chain termination. With incremental improvements in Sanger  
sequencing—including the use of laser-induced fluorescent excitation of energy  
transfer dyes, engineered DNA polymerases, capillary electrophoresis, sample  
25 preparation, informatics, and sequence analysis software—the Sanger sequencing  
platform has been able to maintain its status. Current state-of-the-art Sanger  
based DNA sequencers can produce over 700 bases of clearly readable sequence  
in a single run from templates up to 30 kb in length. However, as with most  
technological inventions, the continual improvements in this sequencing  
30 platform have come to a stagnant plateau, with the current cost estimate for  
producing a high-quality microbial genome draft sequence at around \$10,000 per

megabasepair. Current DNA sequencers based on the Sanger method allow up to 384 samples to be analyzed in parallel.

It is evident that exploiting the complete human genome sequence for clinical medicine and health care requires accurate low-cost and high-throughput DNA sequencing methods. Indeed, both the public (National Human Genome Research Institute, NHGRI) and private genomic sciences sectors (The J. Craig Venter Science Foundation and Archon X prize for genomics) have issued a call for the development of next-generation sequencing technology that will reduce the cost of sequencing to one-ten thousandth of its current cost over the next ten years. Accordingly, to overcome the limitations of current conventional sequencing technologies, a variety of new DNA sequencing methods have been investigated, including sequencing-by-synthesis (SBS) approaches such as pyrosequencing (Ronaghi et al. (1998) *Science* **281**: 363-365), sequencing of single DNA molecules (Braslaysky et al. (2003) *Proc. Natl. Acad. Sci. USA* **100**: 3960-3964), and polymerase colonies ("polony" sequencing) (Mitra et al. (2003) *Anal. Biochem.* **320**: 55-65).

The concept of DNA sequencing-by-synthesis (SBS) was revealed in 1988 with an attempt to sequence DNA by detecting the pyrophosphate group that is generated when a nucleotide is incorporated in a DNA polymerase reaction (Hyman (1999) *Anal. Biochem.* **174**: 423-436). Subsequent SBS technologies were based on additional ways to detect the incorporation of a nucleotide to a growing DNA strand. In general, conventional SBS uses an oligonucleotide primer designed to anneal to a predetermined position of the sample template molecule to be sequenced. The primer-template complex is presented with a nucleotide in the presence of a polymerase enzyme. If the nucleotide is complementary to the position on the sample template molecule that is directly 3' of the end of the oligonucleotide primer, then the DNA polymerase will extend the primer with the nucleotide. The incorporation of the nucleotide and the identity of the inserted nucleotide can then be detected by, e.g., the emission of light, a change in fluorescence, a change in pH (see, e.g., U.S. Pat. No. 7,932,034), a change in enzyme conformation, or some other physical or chemical change in the reaction (see, e.g., WO 1993/023564 and WO 1989/009283; Seo et al. (2005) "Four-color

DNA sequencing by synthesis on a chip using photocleavable fluorescent nucleotides,” *PNAS* **102**: 5926–59). Upon each successful incorporation of a nucleotide, a signal is detected that reflects the occurrence, identity, and number of nucleotide incorporations. Unincorporated nucleotides can then be removed  
5 (e.g., by chemical degradation or by washing) and the next position in the primer-template can be queried with another nucleotide species.

### SUMMARY

In conventional DNA sequencing-by-synthesis using labeled nucleotide  
10 monomers, four different moieties (e.g., a dye or a fluorescent label) are attached to the four nucleotide bases to allow the detector to distinguish the bases from each other by color. For example, some methods label each of the A, C, G, and T with a fluorescent moiety that emits light at a wavelength that is distinguishable from the light emitted by the other three fluorescent moieties, e.g., to produce  
15 light of four different colors associated with each of the four bases.

In contrast, the present technology relies on differences in labeling ratios rather than on only differences in color to identify bases incorporated during a sequencing reaction. In this scheme, each individual nucleotide base is labeled at a specific known ratio of at least two different moieties (e.g., a dye, a fluorescent  
20 label, etc.). As an exemplary embodiment, ATP is labeled with two moieties X and Y in a ratio of 1:0 (all ATP molecules are labeled with moiety X), TTP is labeled with the two moieties X and Y in a ratio of 2:1 (two-thirds of the population of TTP molecules is labeled with moiety X and one-third of the population of TTP molecules is labeled with moiety Y), GTP is labeled with the  
25 two moieties X and Y in a ratio of 1:2 (one-third of the population of GTP molecules is labeled with moiety X and two-thirds of the population of GTP molecules is labeled with moiety Y), and CTP is labeled with the two moieties X and Y in a ratio of 0:1 (all CTP molecules are labeled with moiety Y). Then, according to some embodiments, a polony (e.g., a clonal colony) based sequencing  
30 approach is performed with the sequence determined by detecting the ratio of signals produced by the two dyes after each base incorporation.

In some embodiments, an element of the technology that allows separating and assigning the signal intensities into appropriate base-specific “bins” is the use of a 4-base calibration sequence at the beginning of a sequencing run. This calibration sequence contains each of the 4 bases in a known order to provide a calibration reference, e.g., to calibrate a sequencing instrument to recognize the appropriate signal ratios (and thus, label ratios) for each of the bases.

As a consequence, embodiments of the technology reduce the number of fluorescent dyes needed to identify the four bases (e.g., allowing one to use only the most optimal dyes to acquire a sequence), reduce the number of lasers used to excite labels (e.g., fluorescent moieties), reduce or eliminate optics used to split the optical signal by wavelength, and reduce of the number of detectors for recording incorporation events.

Accordingly, provided herein are methods for sequencing a target nucleic acid, the method comprising: determining a signal ratio produced from a plurality of a nucleotide base in which a first fraction of the plurality is labeled with a first label and a second fraction of the plurality is labeled with a second label; and associating the signal ratio with the nucleotide base to identify the nucleotide base. In some embodiments, the signal ratio produced by the plurality of the nucleotide base is detectably different than a second signal ratio produced by a second plurality of a second nucleotide base. For example, some embodiments provide that the first fraction of the plurality produces a first signal having a first intensity and the second fraction of the plurality produces a second signal having a second intensity and the signal ratio is a ratio of the first intensity relative to the second intensity. In some embodiments, the first intensity is a first fluorescence emission amplitude and the second intensity is a second fluorescence emission amplitude; some embodiments provide that the first intensity is a first peak height and the second intensity is a second peak height.

In some aspects, the technology relates to sequencing nucleic acids using labeled nucleotides. Accordingly, in some embodiments, the methods comprise providing a first plurality of a first nucleotide base and a second plurality of a second nucleotide base, wherein a first ratio of a first portion of the first plurality

labeled with the first label relative to a second portion of the first plurality  
labeled with the second label is detectably different than a second ratio of a third  
portion of the second plurality labeled with the first label relative to a fourth  
portion of the second plurality labeled with the second label. Moreover, some  
5 embodiments further comprise providing a first plurality of a first nucleotide  
base, a second plurality of a second nucleotide base, a third plurality of a third  
nucleotide base, and a fourth plurality of a fourth nucleotide base, wherein a first  
ratio of a first portion of the first plurality labeled with the first label relative to  
a second portion of the first plurality labeled with the second label, a second ratio  
10 of a third portion of the second plurality labeled with the first label relative to a  
fourth portion of the second plurality labeled with the second label, a third ratio  
of a fifth portion of the third plurality labeled with the first label relative to a  
sixth portion of the third plurality labeled with the second label, and a fourth  
ratio of a seventh portion of the fourth plurality labeled with the first label  
15 relative to an eighth portion of the fourth plurality labeled with the second label  
are all detectably different from each other. For example, in some embodiments  
the first nucleotide base is A, the second nucleotide base is C, the third  
nucleotide base is G, and the fourth nucleotide base is T.

The technology relates to using different ratios of two labels to  
20 differentiate nucleotides in a sequencing reaction. Thus, some embodiments  
provide that the first label is a first fluorescent moiety with an emission peak at  
a first wavelength and the second label is a second fluorescent moiety with an  
emission peak at a second wavelength. Moreover, some embodiments comprise  
monitoring a first channel and a second channel, wherein the first label produces  
25 a signal in the first channel and the second label produces a signal in the second  
channel.

In some aspects, the methods are related to sequencing-by-synthesis; thus,  
methods are provided that comprise incorporating by polymerization the  
plurality of the nucleotide base into a plurality of a nucleic acid that is  
30 complementary to the target nucleic acid. Various detection methods are  
contemplated by the present technology. For instance, in some embodiments, the  
methods comprise monitoring signals with an optical device.

In some embodiments, the methods comprise providing a calibration oligonucleotide comprising a known sequence. And, some embodiments comprise analyzing a dataset of ordered signal ratios to produce a nucleotide sequence of the target nucleic acid.

5 In addition, some aspects of the technology relate to compositions comprising a plurality of a nucleotide base wherein a first portion of the plurality is labeled with a first label and a second portion of the plurality is labeled with a second label. In some embodiments, the compositions further comprise a second plurality of a second nucleotide base wherein a third portion of the second  
10 plurality is labeled with the first label and a fourth portion of the second plurality is labeled with the second label and a first ratio of the first portion relative to the second portion is different than a second ratio of the third portion relative to the fourth portion. In some embodiments, the compositions further comprise a third plurality of a third nucleotide base and a fourth plurality of a  
15 fourth nucleotide base, wherein a fifth portion of the third plurality is labeled with the first label and a sixth portion of the third plurality is labeled with the second label, and a seventh portion of the fourth plurality is labeled with the first label and an eighth portion of the fourth plurality is labeled with the second label and a third ratio of the fifth portion relative to the sixth portion is different  
20 than a ratio of the seventh portion relative to the eighth portion and the third and the fourth ratios are both different than the first and the second ratios. For example, in some embodiments the first nucleotide base is A, the second nucleotide base is C, the third nucleotide base is G, and the fourth nucleotide base is T and, in some embodiments, the label is a fluorescent moiety. In some  
25 embodiments, the first, the second, the third, and/or the fourth base is a modified base or a base analogue such as an inosine, isoguanine, isocytosine, a diaminopyrimidine, a xanthine, a nitroazole, a size-expanded base, etc.

While the technology relates in some aspects to nucleotide compositions, the technology also relates to compositions further comprising a target nucleic  
30 acid, a sequencing primer, and a polymerase. Some embodiments of compositions comprise a nucleic acid comprising the nucleotide base.

The methods and compositions are related, for example, to embodiments of systems for sequencing a nucleic acid, wherein the systems comprise: a composition comprising a plurality of a nucleotide base wherein a first portion of the plurality is labeled with a first label and a second portion of the plurality is labeled with a second label; and a calibration oligonucleotide. Some system  
5 embodiments further comprise a sequencing apparatus, some system embodiments further comprise a processor configured to associate a signal ratio with a nucleotide base, and some system embodiments further comprise an output functionality to provide a nucleotide sequence of the nucleic acid.

10 Systems for sequencing a target (template) nucleic acid comprise in some embodiments a second plurality of a second nucleotide base, a third plurality of a third nucleotide base, and a fourth plurality of a fourth nucleotide base, wherein a third portion of the second plurality is labeled with the first label and a fourth portion of the second plurality is labeled with the second label, a fifth portion of  
15 the third plurality is labeled with the first label and a sixth portion of the third plurality is labeled with the second label, and a seventh portion of the fourth plurality is labeled with the first label and an eighth portion of the fourth plurality is labeled with the second label and a first ratio of the first portion relative to the second portion, a second ratio of the third portion to the fourth  
20 portion, a third ratio of the fifth portion to the sixth portion, and a fourth ratio of the seventh portion to the eighth portion are different from one another. Thus, some embodiments also comprise a functionality to detect the first label and the second label and, furthermore, some embodiments comprise a functionality to differentiate the nucleotide base, the second nucleotide base, the third nucleotide  
25 base, and the fourth nucleotide base from one another.

The technology finds use in kits comprising embodiments of the compositions provided for, e.g., practicing embodiments of the methods provided. For example, some embodiments provide a kit for sequencing a nucleic acid, wherein the kit comprises a composition comprising a plurality of a nucleotide  
30 base wherein a first portion of the plurality is labeled with a first label and a second portion of the plurality is labeled with a second label; and a calibration oligonucleotide.



In some embodiments, kits are provided that comprise a second plurality of a second nucleotide base, a third plurality of a third nucleotide base, and a fourth plurality of a fourth nucleotide base, wherein a third portion of the second plurality is labeled with the first label and a fourth portion of the second  
5 plurality is labeled with the second label, a fifth portion of the third plurality is labeled with the first label and a sixth portion of the third plurality is labeled with the second label, and a seventh portion of the fourth plurality is labeled with the first label and an eighth portion of the fourth plurality is labeled with the second label and a first ratio of the first portion relative to the second  
10 portion, a second ratio of the third portion to the fourth portion, a third ratio of the fifth portion to the sixth portion, and a fourth ratio of the seventh portion to the eighth portion are different from one another.

Additional embodiments will be apparent to persons skilled in the relevant art based on the teachings contained herein.

15

### **DETAILED DESCRIPTION**

Provided herein is technology relating to sequencing nucleic acids and particularly, but not exclusively, to methods, compositions, systems, and kits for sequencing a nucleic acid using the ratio between multiple label signals to  
20 differentiate bases.

The section headings used herein are for organizational purposes only and are not to be construed as limiting the described subject matter in any way.

In this detailed description of the various embodiments, for purposes of explanation, numerous specific details are set forth to provide a thorough  
25 understanding of the embodiments disclosed. One skilled in the art will appreciate, however, that these various embodiments may be practiced with or without these specific details. In other instances, structures and devices are shown in block diagram form. Furthermore, one skilled in the art can readily appreciate that the specific sequences in which methods are presented and  
30 performed are illustrative and it is contemplated that the sequences can be varied and still remain within the spirit and scope of the various embodiments disclosed herein.

All literature and similar materials cited in this application, including but not limited to, patents, patent applications, articles, books, treatises, and internet web pages are expressly incorporated by reference in their entirety for any purpose. Unless defined otherwise, all technical and scientific terms used  
5 herein have the same meaning as is commonly understood by one of ordinary skill in the art to which the various embodiments described herein belongs. When definitions of terms in incorporated references appear to differ from the definitions provided in the present teachings, the definition provided in the present teachings shall control.

10 It will be appreciated that there is an implied “about” prior to the temperatures, concentrations, times, etc. discussed in the present teachings, such that insubstantial deviations are within the scope of the present teachings. In this application, the use of the singular includes the plural unless specifically stated otherwise. Also, the use of “comprise”, “comprises”, “comprising”,  
15 “contain”, “contains”, “containing”, “include”, “includes”, and “including” are not intended to be limiting. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the present teachings.

Further, unless otherwise required by context, singular terms shall  
20 include pluralities and plural terms shall include the singular. Generally, nomenclatures utilized in connection with, and techniques of, cell and tissue culture, molecular biology, and protein and oligonucleotide or polynucleotide chemistry and hybridization described herein are those well known and commonly used in the art. Unless otherwise indicated, standard techniques are  
25 used, for example, for nucleic acid purification and preparation, chemical analysis, recombinant nucleic acid, and oligonucleotide synthesis. Enzymatic reactions and purification techniques are performed according to manufacturer’s specifications or as commonly accomplished in the art or as described herein. The techniques and procedures described herein are generally performed according to  
30 conventional methods as described in various general and more specific references that are cited and discussed throughout the instant specification. See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual* (Third ed., Cold

Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2000)). The nomenclatures utilized in connection with, and the laboratory procedures and techniques described herein are those well known and commonly used in the art.

## 5 **Definitions**

To facilitate an understanding of the present technology, a number of terms and phrases are defined below. Additional definitions are set forth throughout the detailed description.

10 Throughout the specification and claims, the following terms take the meanings explicitly associated herein, unless the context clearly dictates otherwise. The phrase “in one embodiment” as used herein does not necessarily refer to the same embodiment, though it may. Furthermore, the phrase “in another embodiment” as used herein does not necessarily refer to a different embodiment, although it may. Thus, as described below, various embodiments of  
15 the invention may be readily combined, without departing from the scope or spirit of the invention.

In addition, as used herein, the term “or” is an inclusive “or” operator and is equivalent to the term “and/or” unless the context clearly dictates otherwise. The term “based on” is not exclusive and allows for being based on additional  
20 factors not described, unless the context clearly dictates otherwise. In addition, throughout the specification, the meaning of “a”, “an”, and “the” include plural references. The meaning of “in” includes “in” and “on.”

A “system” denotes a set of components, real or abstract, comprising a whole where each component interacts with or is related to at least one other  
25 component within the whole.

As used herein, the phrase “dNTP” means deoxynucleotidetriphosphate, where the nucleotide comprises a nucleotide base, such as A, T, C, G or U.

The term “monomer” as used herein means any compound that can be incorporated into a growing molecular chain by a given polymerase. Such  
30 monomers include, without limitations, naturally occurring nucleotides (e.g., ATP, GTP, TTP, UTP, CTP, dATP, dGTP, dTTP, dUTP, dCTP, synthetic analogs), precursors for each nucleotide, non-naturally occurring nucleotides and

their precursors, or any other molecule that can be incorporated into a growing polymer chain by a given polymerase.

As used herein, a “nucleic acid” shall mean any nucleic acid molecule, including, without limitation, DNA, RNA and hybrids thereof. The nucleic acid bases that form nucleic acid molecules can be the bases A, C, G, T and U, as well as derivatives thereof. Derivatives of these bases are well known in the art. The term should be understood to include, as equivalents, analogs of either DNA or RNA made from nucleotide analogs. The term as used herein also encompasses cDNA, that is complementary, or copy, DNA produced from an RNA template, for example by the action of reverse transcriptase. It is well known that DNA (deoxyribonucleic acid) is a chain of nucleotides consisting of 4 types of nucleotides—A (adenine), T (thymine), C (cytosine), and G (guanine)—and that RNA (ribonucleic acid) is a chain of nucleotides consisting of 4 types of nucleotides—A, U (uracil), G, and C. It is also known that all of these 5 types of nucleotides specifically bind to one another in combinations called complementary base pairing. That is, adenine (A) pairs with thymine (T) (in the case of RNA, however, adenine (A) pairs with uracil (U)), and cytosine (C) pairs with guanine (G), so that each of these base pairs forms a double strand. As used herein, “nucleic acid sequencing data”, “nucleic acid sequencing information”, “nucleic acid sequence”, “genomic sequence”, “genetic sequence”, “fragment sequence”, or “nucleic acid sequencing read” denotes any information or data that is indicative of the order of the nucleotide bases (e.g., adenine, guanine, cytosine, and thymine/uracil) in a molecule (e.g., a whole genome, a whole transcriptome, an exome, oligonucleotide, polynucleotide, fragment, etc.) of DNA or RNA.

Reference to a base, a nucleotide, or to another molecule may be in the singular or plural. That is, a base may refer to a single molecule of that base or to a plurality of that base, e.g., in a solution.

As used herein, the phrase “a clonal plurality of nucleic acids” or “a clonal population of nucleic acids” or “a cluster” or “a polony” refers to a set of nucleic acid products that are substantially or completely or essentially identical to each

other, and they are complementary copies of the template nucleic acid strand from which they are synthesized.

As used herein, a “polynucleotide”, also called a nucleic acid, is a covalently linked series of nucleotides in which the 3' position of the pentose of one nucleotide is joined by a phosphodiester group to the 5' position of the next. DNA (deoxyribonucleic acid) and RNA (ribonucleic acid) are biologically occurring polynucleotides in which the nucleotide residues are linked in a specific sequence by phosphodiester linkages. As used herein, the terms “polynucleotide” or “oligonucleotide” encompass any polymer compound having a linear backbone of nucleotides. An “oligodeoxyribonucleotide” or “oligonucleotides”, also termed an “oligomer”, is generally a polynucleotide of a shorter length.

As used herein, “complementary” generally refers to specific nucleotide duplexing to form canonical Watson-Crick base pairs, as is understood by those skilled in the art. However, complementary also includes base-pairing of nucleotide analogs that are capable of universal base-pairing with A, T, G or C nucleotides and locked nucleic acids that enhance the thermal stability of duplexes. One skilled in the art will recognize that hybridization stringency is a determinant in the degree of match or mismatch in the duplex formed by hybridization.

As used herein, “moiety” refers to one of two or more parts into which something may be divided, such as, for example, the various parts of a tether, a molecule or a probe.

A “polymerase” is an enzyme generally for joining 3'-OH 5'-triphosphate nucleotides, oligomers, and their analogs. Polymerases include, but are not limited to, DNA-dependent DNA polymerases, DNA-dependent RNA polymerases, RNA-dependent DNA polymerases, RNA-dependent RNA polymerases, T7 DNA polymerase, T3 DNA polymerase, T4 DNA polymerase, T7 RNA polymerase, T3 RNA polymerase, SP6 RNA polymerase, DNA polymerase 1, Klenow fragment, *Thermophilus aquaticus* DNA polymerase, *Tth* DNA polymerase, Vent DNA polymerase (New England Biolabs), Deep Vent DNA polymerase (New England Biolabs), *Bst* DNA Polymerase Large Fragment,

Stoeffel Fragment, 9° N DNA Polymerase, *Pfu* DNA Polymerase, *Tfl* DNA Polymerase, RepliPHI Phi29 Polymerase, *Tli* DNA polymerase, eukaryotic DNA polymerase beta, telomerase, Terminator polymerase (New England Biolabs), KOD HiFi. DNA polymerase (Novagen), KOD1 DNA polymerase, Q-beta  
5 replicase, terminal transferase, AMV reverse transcriptase, M-MLV reverse transcriptase, Phi6 reverse transcriptase, HIV-1 reverse transcriptase, novel polymerases discovered by bioprospecting, and polymerases cited in U.S. Pat. Appl. Pub. No. 2007/0048748 and in U.S. Pat. Nos. 6,329,178; 6,602,695; and 6,395,524. These polymerases include wild-type, mutant isoforms, and  
10 genetically engineered variants such as *exo*<sup>-</sup> polymerases and other mutants, e.g., that tolerate labeled nucleotides and incorporate them into a strand of nucleic acid.

The term “primer” refers to an oligonucleotide, whether occurring naturally as in a purified restriction digest or produced synthetically, which is  
15 capable of acting as a point of initiation of synthesis when placed under conditions in which synthesis of a primer extension product that is complementary to a nucleic acid strand is induced, (e.g., in the presence of nucleotides and an inducing agent such as DNA polymerase and at a suitable temperature and pH). The primer is preferably single stranded for maximum  
20 efficiency in amplification, but may alternatively be double stranded. If double stranded, the primer is first treated to separate its strands before being used to prepare extension products. Preferably, the primer is an oligodeoxyribonucleotide. The primer must be sufficiently long to prime the synthesis of extension products in the presence of the inducing agent. The exact  
25 lengths of the primers will depend on many factors, including temperature, source of primer and the use of the method.

### **Embodiments of the technology**

The technology relates generally to methods, compositions, systems, and  
30 kits for DNA sequencing using a sequencing-by-synthesis approach. Although the disclosure herein refers to certain illustrated embodiments, it is to be

understood that these embodiments are presented by way of example and not by way of limitation.

## Methods

5           Some embodiments of the technology provide for methods of DNA sequencing-by-synthesis in which different ratios of signal intensities, rather than different signal wavelengths, identify bases incorporated during, for example, a sequencing-by-synthesis reaction. In some embodiments, an ensemble based (e.g., a polymerase colony (“polony”) or clonal colony) sequencing approach  
10 is used. These approaches sequence multiple identical or substantially identical copies of a DNA molecule that form a cluster of template molecules. Methods of forming clusters are provided, e.g., in U.S. Pat. No. 7,115,400. In some embodiments, the clusters are immobilized on a solid support such as a bead. These clusters typically result from amplifying a single originating DNA  
15 molecule; thus, each cluster represents the single molecule that initiated the amplification. For example, in the “bridge amplification” process used in Solexa sequencing, approximately 1 million copies of the original DNA molecule fragment are present in the cluster. Then, depending on the sequencing chemistry and methodology of particular embodiments, bases are added to the  
20 collection of clusters (or, equivalently, colonies, polonies, etc.). In an ensemble method according to the present technology, the ratio of labeling is directly associated with the qualities of the signal produced. For example, a base (e.g., a plurality of a base in solution) labeled at a ratio of 1:1 with two moieties that emit fluorescent signals at two distinct wavelengths will produce an emission  
25 spectrum having two peaks at the two wavelengths; the same amount of the base labeled at a ratio of 1:0 with the two moieties will generally emit a fluorescent signal having a single peak that is twice as intense as either of the peaks for the base when labeled in a 1:1 ratio. The ratio of the relative peak heights (e.g., the signal intensities at two wavelengths) in the spectrum is generally similar to the  
30 ratio of the proportion of a base that is labeled. For example, a population of bases labeled at a ratio of 1:3 with two moieties X and Y will generally produce a spectrum having two peaks (corresponding to the emission wavelengths of X and

Y) whose relative heights are also 1:3. Peak height and signal intensity are related such that the two terms can be used interchangeably. Consequently, the ratio of the signals can be measured, for example, by the ratio of peak heights in a spectrum, other peak characteristics (such as peak area, peak width at half height, etc.) and/or as a ratio of two intensities measured using, e.g., filters or optical splitting. In some embodiments, ratios are corrected using a correction factor related to a difference in the molar emission efficiency for two moieties.

In general, two approaches for base addition are used in ensemble-based sequencing-by-synthesis: in the first, the bases are provided one at a time; in the second, bases are modified with identifying moieties so that the base type of the incorporated nucleotide is identified as synthesis proceeds. In some embodiments, synthesis is synchronously controlled by adding one base at a time (see, e.g., Margulies, M. et al. "Genome sequencing in microfabricated high-density picolitre reactors", *Nature* **437**: 376–380 (2005); Harris, T.D. et al. "Single-molecule DNA sequencing of a viral genome", *Science* **320**: 106–109 (2008)) or by using nucleotides that are reversibly blocked. In particular embodiments, extension is momentarily blocked following each base addition by using modified nucleotides (e.g., nucleotide reversible terminators as described in, e.g., WO2004/018497; U.S. Pat. Appl. Pub. No. 2007/0166705; Bentley, D.R. et al. "Accurate whole human genome sequencing using reversible terminator chemistry", *Nature* **456**: 53–59 (2008); Turcatti, G. et al. "A new class of cleavable fluorescent nucleotides: synthesis and optimization as reversible terminators for DNA sequencing by synthesis", *Nucleic Acids Res.* **36**: e25 (2008); Guo, J. et al. "Four-color DNA sequencing with 3'-O-modified nucleotide reversible terminators and chemically cleavable fluorescent dideoxynucleotides", *Proc. Natl. Acad. Sci. USA* **105**: 9145–9150 (2008); Ju, J. et al. "Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators", *Proc. Natl. Acad. Sci. USA* **103**: 19635–19640 (2006); Seo, T.S. et al. "Four-color DNA sequencing by synthesis on a chip using photocleavable fluorescent nucleotides", *Proc. Natl. Acad. Sci. USA* **102**: 5926–5931 (2005); Wu, W. et al. "Termination of DNA synthesis by N6-alkylated, not 3'-O-alkylated, photocleavable 2'-deoxyadenosine triphosphates", *Nucleic Acids Res.* **35**: 6339–



6349 (2007)) or by omitting reaction components such as divalent metal ions (see, e.g., WO 2005/123957; U.S. Pat. Appl. Pub. No. 20060051807).

Typically, each base addition is followed by a washing step to remove excess reactants. Then, while synthesis is stopped, clusters are imaged to  
5 determine which base was added. In embodiments when one base is added per reaction cycle, the successful incorporation of a base indicates the base (and thus the sequence) at that position. These base additions are detected typically by fluorescence (see, e.g., Harris, supra) or by enzyme cascades that identify the release of pyrophosphate by the production of light (see, e.g., Margulies, supra;  
10 Bentley, supra). According to the technology provided herein, base identity is associated with the ratio of signals (e.g., intensities or spectrum peaks) generated and detected during this detection phase, which, in turn, is associated with the ratio of base labeling.

When all bases are added simultaneously, bases are conventionally  
15 discriminated by different tags (e.g., fluorescent moieties) attached to each base (see, e.g., Korlach, J. et al. "Selective aluminum passivation for targeted immobilization of single DNA polymerase molecules in zero-mode waveguide nanostructures", *Proc. Natl. Acad. Sci. USA* **105**: 1176–1181 (2008); U.S. Pat. Appl. Pub. No. US 20030194740; U.S. Pat. Appl. Pub. No. U.S. Pat. Appl. Pub.  
20 No. US 20030064366; Turcatti, G., et al. "A new class of cleavable fluorescent nucleotides: synthesis and optimization as reversible terminators for DNA sequencing by synthesis", *Nucleic Acids Res.* **36**: e25 (2008); Guo, J. et al. "Four-color DNA sequencing with 3'-O-modified nucleotide reversible terminators and chemically cleavable fluorescent dideoxynucleotides", *Proc. Natl. Acad. Sci. USA*  
25 **105**: 9145–9150 (2008); Ju, J. et al. "Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators", *Proc. Natl. Acad. Sci. USA* **103**: 19635–19640 (2006); Seo, T.S. et al. "Four-color DNA sequencing by synthesis on a chip using photocleavable fluorescent nucleotides", *Proc. Natl. Acad. Sci. USA* **102**: 5926–5931 (2005); Wu, W. et al. "Termination of DNA  
30 synthesis by N6-alkylated, not 3'-O-alkylated, photocleavable 2'-deoxyadenosine triphosphates", *Nucleic Acids Res.* **35**: 6339–6349 (2007); WO 2006/084132). According to embodiments of the technology provided herein, base identity is

associated with a ratio of signals generated (e.g., peak height and/or signal intensity at multiple distinguishable wavelengths), which, in turn, is associated with the ratio of base labeling.

For example, in some embodiments all four nucleotides are added  
5 simultaneously to the reaction comprising DNA polymerase and the clusters of  
template-primer complexes. In some embodiments, the nucleotides carry a  
fluorescent label and the 3' hydroxyl group is chemically blocked (e.g., with a  
labeled reversible terminator) so that synthesis stops after a base is incorporated  
10 into the growing (synthesized) DNA strand. An imaging step follows each base  
incorporation step, during which the clusters are imaged. To image the clusters,  
in some embodiments the fluorescent labels are excited by a laser and then the  
fluorescence emitted from the clusters is recorded. In some embodiments, the  
imaging records the wavelengths and the intensities at those wavelengths of the  
fluorescence emitted. According to the present technology, at least two bases are  
15 labeled using different ratios of two labels and thus differences in the emitted  
ratio of signals at the two wavelengths associated with the two labels  
differentiates the bases from one another. Then, before initiating the next  
synthetic cycle, the 3' terminal blocking groups are removed to provide a  
substrate for the incorporation of the next base. The cycles are repeated in this  
20 fashion to determine the sequence of the templates one base at a time.

In some embodiments each nucleotide is added one at a time to a reaction  
mixture containing the nucleic acid target-primer complex and the polymerase,  
monitoring the reaction for a signal, and removing the base from the reaction.  
For example, an illustrative embodiment of the method comprises:

25

1. providing a sequencing primer, a template, a polymerase, and  
solutions of the four bases A, C, G, and T
2. hybridizing the primer to the template under appropriate chemical  
and physical conditions
- 30 3. adding an aliquot of a solution comprising the A base to the reaction
4. monitoring the reaction for the production of a signal
5. removing the A base from the solution

6. adding an aliquot of a solution comprising the C base to the reaction
7. monitoring the reaction for the production of a signal
8. removing the C base from the solution
9. adding an aliquot of a solution comprising the G base to the reaction
- 5 10. monitoring the reaction for the production of a signal
11. removing the G base from the solution
12. adding an aliquot of a solution comprising the T base to the reaction
13. monitoring the reaction for the production of a signal
14. removing the T base from the solution
- 10 15. repeating steps 3–14 until the template is sequenced.

During each cycle, the detection of an output signal appropriate for the base added in the previous step indicates a successful incorporation of that base and thus identifies the base incorporated at that step. Detection may be by  
15 conventional technology. For example, if the label is a fluorescent moiety, then detection of an incorporated base may be carried out by using a confocal scanning microscope to scan the collection of clusters (e.g., attached to a surface) with a laser to image the fluorescent moieties bound directly to the incorporated bases. Alternatively, a sensitive 2D detector, such as a charge coupled detector (CCD),  
20 can be used to visualize the signals generated. However, other techniques such as scanning near-field optical microscopy (SNOM) are available and may be used when imaging dense arrays. For example, using SNOM, individual polynucleotides may be distinguished when separated by a distance of less than 100 nm, e.g. 10 nm to 10 fm. For a description of scanning near-field optical  
25 microscopy, see Moyer et al., *Laser Focus World* (1993) 29:10. Suitable apparatuses used for imaging polynucleotide arrays are known and the technical set-up will be apparent to the skilled person. The detection is preferably used in combination with an analysis system to determine the number and nature of the nucleotides incorporated for each step of synthesis. This analysis, which may be  
30 carried out immediately after each synthesis step, or later using recorded data, allows the sequence of the nucleic acid template within a given colony to be determined.

While this exemplary embodiment indicates adding the bases in the order A, C, G, and T, the technology is not limited to this order. Indeed, in some embodiments the bases are added in any permuted order of the set {A C G T} or {A C G U}, e.g., A, G, C, T; A, T, C, G; T, C, G, A, etc. In addition, some  
5  
embodiments provide that base analogues, modified bases, and other molecules are added instead of A, C, G, and T. It is to be understood that the nucleotides comprising uridine (“U”) can be used in place of T and vice-versa. If the sequence being determined is unknown, the nucleotides added are usually applied in a chosen order that is then repeated throughout the analysis, for example as  
10  
discussed above. If, however, the sequence being determined is known and is being re-sequenced, for example, to determine if small differences are present in the sequence relative to the known sequence, the sequencing determination process may be made quicker by adding the nucleotides at each step in the appropriate order, chosen according to the known sequence. Differences from the  
15  
given sequence are thus detected by the lack of incorporation of certain nucleotides at particular stages of primer extension.

As an improved method of detecting base addition in SBS, the technology is generally applicable to SBS methods in which bases are differentially labeled to identify them. However, while conventional technologies differentiate bases  
20  
solely by color (e.g., peak position in the wavelength domain), the technology provided herein differentiates bases by differences in the ratio of base labels, e.g., the ratio of signal intensities produced by at least two labels emitting at two distinguishable wavelengths. For example, in some embodiments all four bases are labeled at a different ratio with two labels (e.g., fluorescent moieties).

25  
With respect to sequencing-by-synthesis methods and schemes that find use, e.g., as appropriately adapted to the methods provided herein, Morozova and Marra provide a review of some such technologies in *Genomics* **92**: 255 (2008); additional discussions are found in Mardis, *Annu. Rev. Genomics Hum. Genet.* (2008) **9**:387–402 and in Fuller, et al. (2009) *Nat. Biotechnol.* **27**: 1013.

30  
More specifically, some embodiments provide for the use of bases labeled at different ratios in an ensemble sequencing-by-synthesis technique such as the following: parallel sequencing of partitioned amplicons (PCT Publication No:

WO2006084132); parallel oligonucleotide extension (See, e.g., U.S. Pat. No. 5,750,341; U.S. Pat. No. 6,306,597); polony sequencing (Mitra et al. (2003) *Analytical Biochemistry* **320**: 55-65; Shendure et al. (2005) *Science* **309**: 1728-1732; U.S. Pat. No. 6,432,360, U.S. Pat. No. 6,485,944, U.S. Pat. No. 6,511,803);  
5 the Solexa single base addition technology (see, e.g., Bennett et al. (2005), *Pharmacogenomics* **6**: 373-382; U.S. Pat. No. 6,787,308; U.S. Pat. No. 6,833,246; herein incorporated by reference in their entirety), the Lynx massively parallel signature sequencing technology (Brenner et al. (2000). *Nat. Biotechnol.* **18**: 630-634; U.S. Pat. No. 5,695,934; U.S. Pat. No. 5,714,330), and the Adessi PCR colony  
10 technology (Adessi et al. (2000). *Nucleic Acid Res.* **28**: E87; WO 00018957).

In an exemplary embodiment, Solexa sequencing is used. In the Solexa/Illumina platform (Voelkerding *et al.*, *Clinical Chem.*, *55*: 641-658, 2009; MacLean *et al.*, *Nature Rev. Microbiol.* **7**: 287-296; U.S. Pat. No. 6,833,246; U.S. Pat. No. 7,115,400; U.S. Pat. No. 6,969,488; and U.S. Pat. No. 6,787,308, each  
15 herein incorporated by reference in its entirety), sequencing data are produced in the form of shorter-length reads. In this method, single-stranded fragmented DNA is end-repaired to generate 5'-phosphorylated blunt ends, followed by Klenow-mediated addition of a single A base to the 3' end of the fragments. A-  
addition facilitates addition of T-overhang adaptor oligonucleotides, which are  
20 subsequently used to capture the template-adaptor molecules on the surface of a flow cell that is studded with oligonucleotide anchors. The anchor is used as a PCR primer, but because of the length of the template and its proximity to other nearby anchor oligonucleotides, extension by PCR results in the "arching over" of the molecule to hybridize with an adjacent anchor oligonucleotide to form a  
25 bridge structure (and, after several rounds of amplification, a cluster) on the surface of the flow cell. These loops of DNA are denatured and cleaved. Forward strands are then sequenced with reversible dye terminators. The sequence of incorporated nucleotides is determined by detection of post-incorporation fluorescence (e.g., by differences signal ratios), with each fluor and block removed  
30 prior to the next cycle of dNTP addition. Sequence read length ranges from 36 nucleotides to over 50 nucleotides, with overall output exceeding 1 billion nucleotide pairs per analytical run.

In some embodiments, a calibration sequence is used to differentiate the ratios of signal intensities associated with the bases. For example, such a calibration sequence comprises, in some embodiments, each of the four bases in a known order so that a sequencing instrument is calibrated to recognize the signal intensities (due to the label ratios) expected for each of the bases complementary to the calibration sequence. In some embodiments the calibration sequence is attached to the beginning of each target nucleic acid to be sequenced. In some embodiments, the calibration sequence is not attached to the target sequence but is used to calibrate the sequencing instrument before acquiring the sequence of the target nucleic acid. In some embodiments, the calibration is used for more than one sequencing run. The calibration sequence is any length that provides adequate calibration. In some embodiments the calibration sequence is four bases long; in some embodiments the calibration sequence is 5, 6, 7, 8, 9, 10, 16, 20, 24, 28, 32, 64, or more bases long.

Some embodiments provide methods for the detection of molecules or the labeling of samples using detection reagents labeled with different ratios of at least two labels. Differences in signal ratios identify the molecules and differentiate the molecules from each other. For example, some methods comprise contacting a sample (e.g., a cell, tissue, fluid, etc.) with two or more antibodies wherein each antibody is labeled at a different ratio with at least two moieties; some methods comprise contacting a sample (e.g., a cell, tissue, fluid, etc.) with two or more labeled oligonucleotide probes wherein each probe is labeled at a different ratio with at least two moieties. The methods comprise differentiating two or more molecules, samples, tissues, cells, etc. from each other by associating a difference in signal ratio with a detection reagent and thus with the detection reagent target.

### **Compositions**

The technology provides compositions, e.g., compositions of nucleotide bases alone or in combination (e.g., a mixture) wherein the labeling ratio differs for at least two of the bases. As noted above, the ratio of signals produced and detected during the SBS reaction varies proportionally with the label ratio for

each base. For example, a 2:1 label ratio produces a signal at two wavelengths with a 2:1 ratio of signal intensities (e.g., peak heights).

In some embodiments, the label ratio differs among the four bases, allowing for differentiating each base from the three others, e.g., as each base is incorporated in an ensemble SBS reaction and a signal is produced. As used herein, the “label ratio” refers to the relative fractions of base molecules of one type that are labeled. The label ratio can be any ratio that allows a base to be distinguished from another base labeled at a second label ratio. For instance, if the number of individual A base molecules (e.g., in a solution) is 100 and the number of individual A base molecules that are labeled with label X is 50 and the number of individual A base molecules that are labeled with label Y is 50, then the label ratio for A is 1:1. In this exemplary embodiment, the label ratios for the other three bases C, G, and T, are 1:2, 2:1, and 1:0, respectively. Various embodiments provide label ratios other than these exemplary values. Indeed, any combination label ratios is contemplated by the technology provided that the four bases can be distinguished from one another based on the differences in the label ratios and the subsequent ratios of the signals produced in a SBS reaction. In various embodiments, any of the four bases is labeled at ratio that is 1:0, 1:3, 1:2, 1:1, 2:1, 3:1, and 0:1 with two labels, provided the ratios are sufficient to differentiate the bases from one another.

Compositions provided by the present technology include solutions of four bases wherein at least two bases are labeled with different ratios of at least two labels. Embodiments of compositions generally comprise a buffer known in the art and optionally comprise other salts and preservatives known to those in the art, e.g., to maintain the stability of the composition. Various embodiments include compositions comprising one base or mixtures of 2, 3, 4, or more bases. The bases in these compositions are labeled at different ratios with different labels using identification schemes as discussed above.

Some embodiments provide a composition comprising a calibration oligonucleotide comprising or consisting of a known sequence of bases. In some embodiments, the calibration oligonucleotide comprises or consists of 4, 5, 6, 7, 8

or more bases whose sequence is known. The oligonucleotide is, in some embodiments, synthesized chemically.

### **Data analysis**

5           Some embodiments comprise a computer system upon which embodiments of the present teachings may be implemented. In various embodiments, a computer system includes a bus or other communication mechanism for communicating information and a processor coupled with the bus for processing information. In various embodiments, the computer system includes a memory, which can be a random access memory (RAM) or other dynamic storage device, 10 coupled to the bus for identifying bases (e.g., making “base calls”), and instructions to be executed by the processor. Memory also can be used for storing temporary variables or other intermediate information during execution of instructions to be executed by the processor. In various embodiments, the computer system can further include a read only memory (ROM) or other static storage device coupled to the bus for storing static information and instructions for the processor. A storage device, such as a magnetic disk or optical disk, can be provided and coupled to the bus for storing information and instructions.

          In various embodiments, the computer system is coupled via the bus to a 20 display, such as a cathode ray tube (CRT) or a liquid crystal display (LCD), for displaying information to a computer user. An input device, including alphanumeric and other keys, can be coupled to the bus for communicating information and command selections to the processor. Another type of user input device is a cursor control, such as a mouse, a trackball, or cursor direction keys 25 for communicating direction information and command selections to the processor and for controlling cursor movement on the display. This input device typically has two degrees of freedom in two axes, a first axis (e.g., x) and a second axis (e.g., y), that allows the device to specify positions in a plane.

          A computer system can perform embodiments of the present technology. 30 Consistent with certain implementations of the present teachings, results can be provided by the computer system in response to the processor executing one or more sequences of one or more instructions contained in the memory. Such



instructions can be read into the memory from another computer-readable medium, such as a storage device. Execution of the sequences of instructions contained in the memory can cause the processor to perform the methods described herein. Alternatively, hard-wired circuitry can be used in place of or in combination with software instructions to implement the present teachings. Thus implementations of the present teachings are not limited to any specific combination of hardware circuitry and software.

The term “computer-readable medium” as used herein refers to any media that participates in providing instructions to the processor for execution. Such a medium can take many forms, including but not limited to, non-volatile media, volatile media, and transmission media. Examples of non-volatile media can include, but are not limited to, optical or magnetic disks. Examples of volatile media can include, but are not limited to, dynamic and flash memory. Examples of transmission media can include, but are not limited to, coaxial cables, copper wire, and fiber optics, including the wires that comprise the bus.

Common forms of computer-readable media include, for example, a floppy disk, a flexible disk, hard disk, magnetic tape, or any other magnetic medium, a CD-ROM, any other optical medium, punch cards, paper tape, any other physical medium with patterns of holes, a RAM, PROM, and EPROM, a FLASH-EPROM, any other memory chip or cartridge, or any other tangible medium from which a computer can read.

Various forms of computer readable media can be involved in carrying one or more sequences of one or more instructions to the processor for execution. For example, the instructions can initially be carried on the magnetic disk of a remote computer. The remote computer can load the instructions into its dynamic memory and send the instructions over a network connection (e.g., a LAN, a WAN, the internet, a telephone line). A local computer system can receive the data and transmit it to the bus. The bus can carry the data to the memory, from which the processor retrieves and executes the instructions. The instructions received by the memory may optionally be stored on a storage device either before or after execution by the processor.

In accordance with various embodiments, instructions configured to be executed by a processor to perform a method are stored on a computer-readable medium. The computer-readable medium can be a device that stores digital information. For example, a computer-readable medium includes a compact disc  
5 read-only memory (CD-ROM) as is known in the art for storing software. The computer-readable medium is accessed by a processor suitable for executing instructions configured to be executed.

In accordance with such a computer system, some embodiments of the technology provided herein further comprise functionalities for collecting,  
10 storing, and/or analyzing data (e.g., nucleotide sequence data). For example, some embodiments contemplate a system that comprises a processor, a memory, and/or a database for, e.g., storing and executing instructions, analyzing imaging data from a SBS reaction, performing calculations using the data, transforming the data, and storing the data. In some embodiments, a base-calling algorithm  
15 assigns a sequence of bases to the data and associates quality scores to base calls based on a statistical model. In some embodiments, the system is configured to assemble a sequence from multiple sub-sequences, in some instances accounting for overlap and calculating a consensus sequence. In some embodiments, a sequence determined from a SBS reaction is aligned to a reference sequence or to  
20 a scaffold.

Many diagnostics involve determining the presence of, or a nucleotide sequence of, one or more nucleic acids. Thus, in some embodiments, an equation comprising variables representing the presence or sequence properties of  
25 multiple nucleic acids produces a value that finds use in making a diagnosis or assessing the presence or qualities of a nucleic acid. As such, in some embodiments this value is presented by a device, e.g., by an indicator related to the result (e.g., an LED, an icon on an LCD, a sound, or the like). In some embodiments, a device stores the value, transmits the value, or uses the value for additional calculations.

30 Moreover, in some embodiments a processor is configured to control the sequencing reactions and collect the data (e.g., images). In some embodiments, the processor is used to initiate and/or terminate each round of sequencing and

data collection relating to a sequencing reaction. Some embodiments comprise a processor configured to analyze the dataset of signal ratios acquired during the SBS reaction and discern the sequence of the target nucleic acid and/or of its complement.

5           In some embodiments, a device that comprises a user interface (e.g., a keyboard, buttons, dials, switches, and the like) for receiving user input is used by the processor to direct a measurement. In some embodiments, the device further comprises a data output for transmitting (e.g., by a wired or wireless connection) data to an external destination, e.g., a computer, a display, a  
10 network, and/or an external storage medium.

          In some embodiments, the technology finds use in assaying the presence of one or more nucleic acids and/or providing the sequence of one or more nucleic acids. Accordingly, the technology provided herein finds use in the medical, clinical, and emergency medical fields. In some embodiments a device is used to  
15 assay biological samples. In such an assay, the biological sample comprises a nucleic acid and sequencing the nucleic acid is indicative of a state or a property of the sample and, in some embodiments, the subject from which the sample was taken. Some relevant samples include, but are not limited to, whole blood, lymph, plasma, serum, saliva, urine, stool, perspiration, mucus, tears,  
20 cerebrospinal fluid, nasal secretion, cervical or vaginal secretion, semen, pleural fluid, amniotic fluid, peritoneal fluid, middle ear fluid, joint fluid, gastric aspirate, a tissue homogenate, a cell homogenate, or the like.

          The sequence of output signals provides the sequence of the synthesized DNA and, by the rules of base complementarity, also thus provides the sequence  
25 of the template strand.

### **Apparatuses**

          A further aspect of the invention provides an apparatus for carrying out the methods or for preparing the compositions of the technology. Such apparatus  
30 might comprise, for example, a plurality of nucleic acid templates and primers bound, preferably covalently, to a solid support, together with a nucleic acid polymerase, a plurality of nucleotide precursors such as those described above,

which are labeled according to a label ratio, and a functionality for controlling temperature and/or nucleotide additions. Preferably the apparatus also comprises a detecting functionality for detecting and distinguishing signals from individual nucleic acid clusters. Such a detecting functionality might comprise a charge-coupled device operatively connected to a magnifying device such as a microscope. Preferably any apparatuses of the invention are provided in an automated form, e.g., under the control of a program of steps and decisions, e.g., as implemented in computer software.

Some embodiments of such an apparatus include a fluidic delivery and control unit; a sample processing unit; a signal detection unit; and a data acquisition, analysis, and control unit. Various embodiments of the apparatus can provide for automated sequencing that can be used to gather sequence information from a plurality of sequences in parallel, e.g., substantially simultaneously.

In various embodiments, the fluidics delivery and control unit includes a reagent delivery system. The reagent delivery system can include a reagent reservoir for the storage of various reagents (e.g., compositions of nucleotides according to the technology). The reagents can include RNA-based primers, forward/reverse DNA primers, oligonucleotide mixtures for ligation sequencing, nucleotide mixtures for sequencing-by-synthesis, buffers, wash reagents, blocking reagent, stripping reagents, and the like. Additionally, the reagent delivery system can include a pipetting system or a continuous flow system that connects the sample processing unit with the reagent reservoir.

In various embodiments, the sample processing unit can include a sample chamber, such as flow cell, a substrate, a micro-array, a multi-well tray, or the like. The sample processing unit can include multiple lanes, multiple channels, multiple wells, or other modes of processing multiple sample sets substantially simultaneously. Additionally, the sample processing unit can include multiple sample chambers to enable processing of multiple runs simultaneously. In particular embodiments, the system can perform signal detection on one sample chamber while substantially simultaneously processing another sample

chamber. Additionally, the sample processing unit can include an automation system for moving or manipulating the sample chamber.

In various embodiments, the signal detection unit can include an imaging or detection sensor. The signal detection unit can include an excitation system to cause a probe, such as a fluorescent dye, to emit a signal. The excitation system can include an illumination source, such as arc lamp, a laser, a light emitting diode (LED), or the like. In particular embodiments, the signal detection unit can include optics for the transmission of light from an illumination source to the sample or from the sample to the imaging or detection sensor. Alternatively, the signal detection unit may not include an illumination source, such as for example, when a signal is produced spontaneously as a result of a sequencing reaction. For example, a signal can be produced by the interaction of a released moiety, such as a released ion interacting with an ion sensitive layer, or a pyrophosphate reacting with an enzyme or other catalyst to produce a chemiluminescent signal.

In various embodiments, a data acquisition analysis and control unit can monitor various system parameters. The system parameters can include the temperature of various portions of the instrument, such as a sample processing unit or reagent reservoirs, volumes of various reagents, the status of various system subcomponents, such as a manipulator, a stepper motor, a pump, or the like, or any combination thereof.

It will be appreciated by one skilled in the art that various embodiments of such an instrument can be used to practice a variety of sequencing methods including ligation-based methods, sequencing by synthesis, single molecule methods, and other sequencing techniques. Ligation sequencing can include single ligation techniques, or change ligation techniques where multiple ligations are performed in sequence on a single primary. Sequencing by synthesis can include the incorporation of dye labeled nucleotides, chain termination, or the like. Single molecule techniques can include staggered sequencing, where the sequencing reactions are paused to determine the identity of the incorporated nucleotide.

In various embodiments, the sequencing instrument can determine the sequence of a nucleic acid, such as a polynucleotide or an oligonucleotide. The nucleic acid can include DNA or RNA, and can be single stranded, such as ssDNA and RNA, or double stranded, such as dsDNA or a RNA/cDNA pair. In various embodiments, the nucleic acid can include or be derived from a fragment library, a mate pair library, a ChIP fragment, or the like. In particular  
5       embodiments, the sequencing instrument can obtain the sequence information from a group of substantially identical nucleic acid molecules.

In various embodiments, the sequencing instrument can output nucleic acid sequencing read data in a variety of different output data file types/formats, including, but not limited to: \*.fasta, \*.csfasta, \*seq.txt, \*qseq.txt, \*.fastq, \*.sff, \*prb.txt, \*.sms, \*srs and/or \*.qv.  
10

Some embodiments comprise a system for reconstructing a nucleic acid sequence in accordance with the various embodiments provided herein. The system can include a nucleic acid sequencer, a sample sequence data storage, a reference sequence data storage, and an analytics computing device/server/node. In various embodiments, the analytics computing device/server/node can be a workstation, a mainframe computer, a personal computer, a mobile device, etc.  
15

The nucleic acid sequencer can be configured to analyze (e.g., interrogate) a nucleic acid fragment (e.g., single fragment, mate-pair fragment, paired-end fragment, etc.) utilizing all appropriate varieties of techniques, platforms, or technologies to obtain nucleic acid sequence information, e.g., using an ensemble sequencing by synthesis. In various embodiments, the nucleic acid sequencer can be in communications with the sample sequence data storage either directly via a data cable (e.g., a serial cable, a direct cable connection, etc.) or bus linkage or, alternatively, through a network connection (e.g., Internet, LAN, WAN, VPN, etc.). In various embodiments, the network connection can be a “hardwired” physical connection. For example, the nucleic acid sequencer can be communicatively connected (via Category 5 (CAT5), fiber optic, or equivalent  
20       cabling) to a data server that can be communicatively connected (via CAT5, fiber optic, or equivalent cabling) through the internet and to the sample sequence data storage. In various embodiments, the network connection can be a wireless  
25

network connection (e.g., Wi-Fi, WLAN, etc.), for example, utilizing an 802.11b/g or equivalent transmission format. In practice, the network connection utilized is dependent upon the particular requirements of the system. In various embodiments, the sample sequence data storage can be an integrated part of the nucleic acid sequencer.

In various embodiments, the sample sequence data storage can be any database storage device, system, or implementation (e.g., data storage partition, etc.) that is configured to organize and store nucleic acid sequence read data generated by the nucleic acid sequencer such that the data can be searched and retrieved manually (e.g., by a database administrator/client operator) or automatically by way of a computer program/application/software script. In various embodiments, the reference data storage can be any database device, storage system, or implementation (e.g., data storage partition, etc.) that is configured to organize and store reference sequences (e.g., whole/partial genome, whole/partial exome, etc.) such that the data can be searched and retrieved manually (e.g., by a database administrator/client operator) or automatically by way of a computer program/application/software script. In various embodiments, the sample nucleic acid sequencing read data can be stored on the sample sequence data storage and/or the reference data storage in a variety of different data file types/formats, including, but not limited to: \*.fasta, \*.csfasta, \*.seq.txt, \*.qseq.txt, \*.fastq, \*.sff, \*.prb.txt, \*.sms, \*.srs and/or \*.qv.

In various embodiments, the sample sequence data storage and the reference data storage are independent standalone devices/systems or implemented on different devices. In various embodiments, the sample sequence data storage and the reference data storage are implemented on the same device/system. In various embodiments, the sample sequence data storage and/or the reference data storage can be implemented on the analytics computing device/server/node.

The analytics computing device/server/node can be in communications with the sample sequence data storage and the reference data storage either directly via a data cable (e.g., serial cable, direct cable connection, etc.) or bus linkage or, alternatively, through a network connection (e.g., Internet, LAN,

WAN, VPN, etc.). In various embodiments, the analytics computing device/server/node can host a reference mapping engine, a de novo mapping module, and/or a tertiary analysis engine. In various embodiments, the reference mapping engine can be configured to obtain sample nucleic acid sequence reads from the sample data storage and map them against one or more reference sequences obtained from the reference data storage to assemble the reads into a sequence that is similar but not necessarily identical to the reference sequence using all varieties of reference mapping/ alignment techniques and methods. The reassembled sequence can then be further analyzed by one or more optional tertiary analysis engines to identify differences in the genetic makeup (genotype), gene expression, or epigenetic status of individuals that can result in large differences in physical characteristics (phenotype). For example, in various embodiments, the tertiary analysis engine can be configured to identify various genomic variants (in the assembled sequence) due to mutations, recombination/crossover, or genetic drift. Examples of types of genomic variants include, but are not limited to: single nucleotide polymorphisms (SNPs), copy number variations (CNVs), insertions/deletions (Indels), inversions, etc.

The optional de novo mapping module can be configured to assemble sample nucleic acid sequence reads from the sample data storage into new and previously unknown sequences.

It should be understood, however, that the various engines and modules hosted on the analytics computing device/server/node can be combined or collapsed into a single engine or module, depending on the requirements of the particular application or system architecture. Moreover, in various embodiments, the analytics computing device/server/node can host additional engines or modules as needed by the particular application or system architecture.

In various embodiments, the mapping and/or tertiary analysis engines are configured to process the nucleic acid and/or reference sequence reads in signal ratio space. In various embodiments, the sample nucleic acid sequencing read and referenced sequence data can be supplied to the analytics computing device/server/node in a variety of different input data file types/formats,



including, but not limited to: \*.fasta, \*.csfasta, \*seq.txt, \*qseq.txt, \*.fastq, \*.sff, \*prb.txt, \*.sms, \*srs and/or \*.qv.

### Uses

5           The technology provides the use of the methods of the technology, or the compositions of the technology, for sequencing and/or re-sequencing nucleic acid molecules for gene expression monitoring, genetic diversity profiling, diagnosis, screening, whole genome sequencing, whole genome polymorphism discovery and scoring, or any other application involving the analysis of nucleic acids where  
10           sequence or partial sequence information is relevant.

### Kits

          A yet further aspect of the invention provides a kit for use in sequencing, re-sequencing, gene expression monitoring, genetic diversity profiling, diagnosis,  
15           screening, whole genome sequencing, whole genome polymorphism discovery and scoring, or any other application involving the sequencing of nucleic acids. In some embodiments, kits comprise at least one plurality of a nucleotide labeled with at least two labels and, optionally, a calibration oligonucleotide comprising a known sequence. In some embodiments, a kit is provided for the detection of  
20           molecules using detection reagents labeled with different label ratios. Differences in signal ratio identify the molecules and differentiate the molecules from each other. For example, some kits comprise an antibody labeled with at least two labels at a defined ratio; some kits comprise an oligonucleotide probe labeled with at least two labels at a defined ratio.

25           Moreover, processes and systems for sequencing that may be adapted for use with the technology are described in, for example, U.S. Patent Nos. 7,405,281, entitled “Fluorescent nucleotide analogs and uses therefor”, issued July 29, 2008 to Xu et al.; 7,315,019, entitled “Arrays of optical confinements and uses thereof”, issued January 1, 2008 to Turner et al.; 7,313,308, entitled  
30           “Optical analysis of molecules”, issued December 25, 2007 to Turner et al.; 7,302,146, entitled “Apparatus and method for analysis of molecules”, issued

November 27, 2007 to Turner et al.; and 7,170,050, entitled "Apparatus and methods for optical analysis of molecules", issued January 30, 2007 to Turner et al.; and U.S. Pat. Pub. Nos. 20080212960, entitled "Methods and systems for simultaneous real-time monitoring of optical signals from multiple sources", filed 5 October 26, 2007 by Lundquist et al.; 20080206764, entitled "Flowcell system for single molecule detection", filed October 26, 2007 by Williams et al.; 20080199932, entitled "Active surface coupled polymerases", filed October 26, 2007 by Hanzel et al.; 20080199874, entitled "CONTROLLABLE STRAND SCISSION OF MINI CIRCLE DNA", filed February 11, 2008 by Otto et al.; 10 20080176769, entitled "Articles having localized molecules disposed thereon and methods of producing same", filed October 26, 2007 by Rank et al.; 20080176316, entitled "Mitigation of photodamage in analytical reactions", filed October 31, 2007 by Eid et al.; 20080176241, entitled "Mitigation of photodamage in analytical reactions", filed October 31, 2007 by Eid et al.; 20080165346, entitled 15 "Methods and systems for simultaneous real-time monitoring of optical signals from multiple sources", filed October 26, 2007 by Lundquist et al.; 20080160531, entitled "Uniform surfaces for hybrid material substrates and methods for making and using same", filed October 31, 2007 by Korlach; 20080157005, entitled "Methods and systems for simultaneous real-time monitoring of optical 20 signals from multiple sources", filed October 26, 2007 by Lundquist et al.; 20080153100, entitled "Articles having localized molecules disposed thereon and methods of producing same", filed October 31, 2007 by Rank et al.; 20080153095, entitled "CHARGE SWITCH NUCLEOTIDES", filed October 26, 2007 by Williams et al.; 20080152281, entitled "Substrates, systems and methods for 25 analyzing materials", filed October 31, 2007 by Lundquist et al.; 20080152280, entitled "Substrates, systems and methods for analyzing materials", filed October 31, 2007 by Lundquist et al.; 20080145278, entitled "Uniform surfaces for hybrid material substrates and methods for making and using same", filed October 31, 2007 by Korlach; 20080128627, entitled "SUBSTRATES, SYSTEMS 30 AND METHODS FOR ANALYZING MATERIALS", filed August 31, 2007 by Lundquist et al.; 20080108082, entitled "Polymerase enzymes and reagents for enhanced nucleic acid sequencing", filed October 22, 2007 by Rank et al.;

20080095488, entitled "SUBSTRATES FOR PERFORMING ANALYTICAL REACTIONS", filed June 11, 2007 by Foquet et al.; 20080080059, entitled "MODULAR OPTICAL COMPONENTS AND SYSTEMS INCORPORATING SAME", filed September 27, 2007 by Dixon et al.; 20080050747, entitled "Articles  
5 having localized molecules disposed thereon and methods of producing and using same", filed August 14, 2007 by Korlach et al.; 20080032301, entitled "Articles having localized molecules disposed thereon and methods of producing same", filed March 29, 2007 by Rank et al.; 20080030628, entitled "Methods and systems for simultaneous real-time monitoring of optical signals from multiple  
10 sources", filed February 9, 2007 by Lundquist et al.; 20080009007, entitled "CONTROLLED INITIATION OF PRIMER EXTENSION", filed June 15, 2007 by Lyle et al.; 20070238679, entitled "Articles having localized molecules disposed thereon and methods of producing same", filed March 30, 2006 by Rank et al.; 20070231804, entitled "Methods, systems and compositions for monitoring  
15 enzyme activity and applications thereof", filed March 31, 2006 by Korlach et al.; 20070206187, entitled "Methods and systems for simultaneous real-time monitoring of optical signals from multiple sources", filed February 9, 2007 by Lundquist et al.; 20070196846, entitled "Polymerases for nucleotide analogue incorporation", filed December 21, 2006 by Hanzel et al.; 20070188750, entitled  
20 "Methods and systems for simultaneous real-time monitoring of optical signals from multiple sources", filed July 7, 2006 by Lundquist et al.; 20070161017, entitled "MITIGATION OF PHOTODAMAGE IN ANALYTICAL REACTIONS", filed December 1, 2006 by Eid et al.; 20070141598, entitled "Nucleotide Compositions and Uses Thereof", filed November 3, 2006 by Turner et al.;  
25 20070134128, entitled "Uniform surfaces for hybrid material substrate and methods for making and using same", filed November 27, 2006 by Korlach; 20070128133, entitled "Mitigation of photodamage in analytical reactions", filed December 2, 2005 by Eid et al.; 20070077564, entitled "Reactive surfaces, substrates and methods of producing same", filed September 30, 2005 by  
30 Roitman et al.; 20070072196, entitled "Fluorescent nucleotide analogs and uses therefore", filed September 29, 2005 by Xu et al; and 20070036511, entitled "Methods and systems for monitoring multiple optical signals from a single

source”, filed August 11, 2005 by Lundquist et al.; and Korlach et al. (2008) “Selective aluminum passivation for targeted immobilization of single DNA polymerase molecules in zero-mode waveguide nanostructures” PNAS 105(4): 1176–81, all of which are herein incorporated by reference in their entireties.

5           Various modifications and variations of the described compositions, methods, and uses of the technology will be apparent to those skilled in the art without departing from the scope and spirit of the technology as described. Although the technology has been described in connection with specific exemplary embodiments, it should be understood that the invention as claimed  
10           should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in related fields are intended to be within the scope of the following claims.

**CLAIMS**

## WE CLAIM:

- 5 1. A method for sequencing a target nucleic acid, the method comprising:
- a) determining a signal ratio produced from a plurality of a nucleotide base in which a first fraction of the plurality is labeled with a first label and a second fraction of the plurality is labeled with a second label; and
- 10 b) associating the signal ratio with the nucleotide base to identify the nucleotide base.
2. The method of claim 1 wherein the signal ratio produced by the plurality of the nucleotide base is detectably different than a second signal ratio
- 15 produced by a second plurality of a second nucleotide base.
3. The method of claim 1 wherein the first fraction of the plurality produces a first signal having a first intensity and the second fraction of the plurality produces a second signal having a second intensity and the signal ratio is
- 20 a ratio of the first intensity relative to the second intensity.
4. The method of claim 3 wherein the first intensity is a first fluorescence emission amplitude and the second intensity is a second fluorescence emission amplitude.
- 25 5. The method of claim 3 wherein the first intensity is a first peak height and the second intensity is a second peak height.
6. The method of claim 1 further comprising providing a first plurality of a first nucleotide base and a second plurality of a second nucleotide base, wherein a first ratio of a first portion of the first plurality labeled with the first label relative to a second portion of the first plurality labeled with the
- 30

second label is detectably different than a second ratio of a third portion of the second plurality labeled with the first label relative to a fourth portion of the second plurality labeled with the second label.

- 5 7. The method of claim 1 further comprising providing a first plurality of a first nucleotide base, a second plurality of a second nucleotide base, a third plurality of a third nucleotide base, and a fourth plurality of a fourth nucleotide base, wherein a first ratio of a first portion of the first plurality labeled with the first label relative to a second portion of the first plurality labeled with the second label, a second ratio of a third portion of the second plurality labeled with the first label relative to a fourth portion of the second plurality labeled with the second label, a third ratio of a fifth portion of the third plurality labeled with the first label relative to a sixth portion of the third plurality labeled with the second label, and a fourth ratio of a seventh portion of the fourth plurality labeled with the first label relative to an eighth portion of the fourth plurality labeled with the second label are all detectably different from each other.
- 10
- 15
- 20 8. The method of claim 7 wherein the first nucleotide base is A, the second nucleotide base is C, the third nucleotide base is G, and the fourth nucleotide base is T.
- 25 9. The method of claim 7 wherein the first label is a first fluorescent moiety with an emission peak at a first wavelength and the second label is a second fluorescent moiety with an emission peak at a second wavelength.
- 30 10. The method of claim 1 further comprising monitoring a first channel and a second channel, wherein the first label produces a signal in the first channel and the second label produces a signal in the second channel.

11. The method of claim 1 further comprising incorporating by polymerization the plurality of the nucleotide base into a plurality of a nucleic acid that is complementary to the target nucleic acid.
- 5 12. The method of claim 10 comprising monitoring with an optical device.
13. The method of claim 1 further comprising providing a calibration oligonucleotide comprising a known sequence.
- 10 14. The method of claim 1 further comprising analyzing a dataset of ordered signal ratios to produce a nucleotide sequence of the target nucleic acid.
15. A composition comprising a plurality of a nucleotide base wherein a first portion of the plurality is labeled with a first label and a second portion of  
15 the plurality is labeled with a second label.
16. The composition of claim 15 further comprising a second plurality of a second nucleotide base wherein a third portion of the second plurality is labeled with the first label and a fourth portion of the second plurality is  
20 labeled with the second label and a first ratio of the first portion relative to the second portion is different than a second ratio of the third portion relative to the fourth portion.
17. The composition of claim 16 further comprising a third plurality of a third  
25 nucleotide base and a fourth plurality of a fourth nucleotide base, wherein a fifth portion of the third plurality is labeled with the first label and a sixth portion of the third plurality is labeled with the second label, and a seventh portion of the fourth plurality is labeled with the first label and an eighth portion of the fourth plurality is labeled with the second label  
30 and a third ratio of the fifth portion relative to the sixth portion is different than a ratio of the seventh portion relative to the eighth portion

and the third and the fourth ratios are both different than the first and the second ratios.

- 5 18. The composition of claim 18 wherein the first nucleotide base is A, the second nucleotide base is C, the third nucleotide base is G, and the fourth nucleotide base is T.
19. The composition of claim 15 wherein the label is a fluorescent moiety.
- 10 20. The composition of claim 15 further comprising a target nucleic acid, a sequencing primer, and a polymerase.
21. The composition of claim 15 further comprising a nucleic acid comprising the nucleotide base.
- 15 22. A system for sequencing a nucleic acid, wherein the system comprises:  
a) a composition comprising a plurality of a nucleotide base wherein a first portion of the plurality is labeled with a first label and a second portion of the plurality is labeled with a second label; and  
20 b) a calibration oligonucleotide.
23. The system of claim 22 further comprising a sequencing apparatus.
24. The system of claim 22 further comprising a processor configured to  
25 associate a signal ratio with a nucleotide base.
25. The system of claim 22 further comprising an output functionality to provide a nucleotide sequence of the nucleic acid.
- 30 26. The system of claim 22 further comprising a second plurality of a second nucleotide base, a third plurality of a third nucleotide base, and a fourth plurality of a fourth nucleotide base, wherein a third portion of the second



5 plurality is labeled with the first label and a fourth portion of the second  
plurality is labeled with the second label, a fifth portion of the third  
plurality is labeled with the first label and a sixth portion of the third  
plurality is labeled with the second label, and a seventh portion of the  
5 fourth plurality is labeled with the first label and an eighth portion of the  
fourth plurality is labeled with the second label and a first ratio of the first  
portion relative to the second portion, a second ratio of the third portion to  
the fourth portion, a third ratio of the fifth portion to the sixth portion,  
and a fourth ratio of the seventh portion to the eighth portion are different  
10 from one another.

27. The system of claim 22 further comprising a functionality to detect the  
first label and the second label.
- 15 28. The system of claim 26 further comprising a functionality to differentiate  
the nucleotide base, the second nucleotide base, the third nucleotide base,  
and the fourth nucleotide base from one another.
29. A kit for sequencing a nucleic acid, wherein the kit comprises:  
20 a) a composition comprising a plurality of a nucleotide base wherein a  
first portion of the plurality is labeled with a first label and a second  
portion of the plurality is labeled with a second label; and  
b) a calibration oligonucleotide.
- 25 30. The kit of claim 29 further comprising a second plurality of a second  
nucleotide base, a third plurality of a third nucleotide base, and a fourth  
plurality of a fourth nucleotide base, wherein a third portion of the second  
plurality is labeled with the first label and a fourth portion of the second  
plurality is labeled with the second label, a fifth portion of the third  
30 plurality is labeled with the first label and a sixth portion of the third  
plurality is labeled with the second label, and a seventh portion of the  
fourth plurality is labeled with the first label and an eighth portion of the

fourth plurality is labeled with the second label and a first ratio of the first portion relative to the second portion, a second ratio of the third portion to the fourth portion, a third ratio of the fifth portion to the sixth portion, and a fourth ratio of the seventh portion to the eighth portion are different from one another.

5

**INTERNATIONAL SEARCH REPORT**

International application No.

PCT/US13/39298

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(8) - C12Q 1/68; C07H 21/04; C12P 19/34 (2013.01)

USPC - 435/6.1, 6.12; 536/24.3

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): C12Q 1/68; C07H 21/04; C12P 19/34 (2013.01)

USPC: 435/6.1, 6.12; 536/24.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MicroPatent (US-G, US-A, EP-A, EP-B, WO, JP-bib, DE-C,B, DE-A, DE-T, DE-U, GB-A, FR-A);DialogPRO; Google; Google Scholar; Pubmed; sequencing, ratio, dual, fluorescent, fluorophore, label; 'nucleic acid'

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X ---	US 5436130 A (MATHIES, RA et al.) July 25, 1995; abstract; figures 1-5; columns 3-10	1-12, 14-21
Y		13, 22-30
Y	WO 2005/089128 A2 (SAMPATH, R et al.) September 29, 2005; abstract; paragraphs [00157]-[00162], [00221], [00223], [00225]	13, 22-30
A	CHEN, DY et al. Two-Label Peak-Height Encoded DNA Sequencing By Capillary Gel Electrophoresis: Three Examples. Nucleic Acids Research. 12 August 1992, Vol. 20, No. 18, pp 4873-4880; entire document.	1-30

Further documents are listed in the continuation of Box C.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search  
06 September 2013 (06.09.2013)

Date of mailing of the international search report

**01 OCT 2013**

Name and mailing address of the ISA/US  
Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
P.O. Box 1450, Alexandria, Virginia 22313-1450  
Facsimile No. 571-273-3201

Authorized officer:  
Shane Thomas

PCT Helpdesk: 571-272-4300  
PCT OSP: 571-272-7774